Drug Approval | August 27, 2022
Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Lutio has the potential to offer significant cost savings when available to UK patients.
Lutio has the potential to offer significant cost savings when available to UK patients.
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
The citizens of Oman will soon have a coordination center that will provide end to end services for healthcare facilities of Jaslok.
The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Subscribe To Our Newsletter & Stay Updated
